

[illegible]

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B (07-06)

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/698,099
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1648
				Examiner Name	Michelle S. Horning
Sheet	2	of	2	Attorney Docket Number	015270-008930US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
/MH/	AA	CHANG et al., "Adjuvant activity of incomplete Freund's adjuvant," <u>Advanced Drug Delivery Reviews</u> , 32:173-186 (1998).		
/MH/	AB	HARLOW et al., eds., page 98 from <i>Antibodies, A Laboratory Manual</i> , Cold Spring Harbor Laboratory (1988).		
/MH/	AC	IWAI et al., "The Precursor Protein of Non-A β Component of Alzheimer's Disease Amyloid Is a Presynaptic Protein of the Central Nervous System," <u>Neuron</u> , 14:467-475 (1995).		

Examiner Signature	/Michelle Horning/	Date Considered	05/24/2007
-----------------------	--------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (07-06)

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/698,099
Filing Date	October 31, 2003
First Named Inventor	Schenk, Dale B.
Art Unit	1648
Examiner Name	Michelle S. Horning
Attorney Docket Number	015270-008930US

Sheet	1	of	3
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)				
/MH/	AA	US-7,060,464		06-13-2006	Kim	
	AB	US-6,923,694		08-02-2005	Kim	
	AC	US-6,890,535		05-10-2005	Schenk	
	AD	US-6,866,850		03-15-2005	Schenk	
	AE	US-6,866,849		03-15-2005	Schenk	
	AF	US-6,858,704		02-22-2005	Kim	
	AG	US-6,787,144		09-07-2004	Schenk	
	AH	US-6,787,143		09-07-2004	Schenk	
	AI	US-6,787,140		09-07-2004	Schenk	
	AJ	US-6,787,139		09-07-2004	Schenk	
	AK	US-6,787,138		09-07-2004	Schenk	
	AL	US-6,761,888		07-13-2004	Schenk	
	AM	US-6,743,427		06-01-2004	Schenk	
	AN	US-6,504,080 B1		01-07-2003	Van Der Putten	
	AO	US-2005/0203010 A1		09-15-2005	Kim	
	AP	US-2005/0255113 A1		11-17-2005	Huston et al.	
	AQ	US-2003/0086938 A1		05-08-2003	Jensen et al.	
	AR	US-2002/0094335 A1		07-18-2002	Chalifour et al.	
	AS	US-2002/0187157 A1		12-12-2002	Jensen et al.	
	AT	US-2002/0151464 A1		10-17-2002	Wolozin et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	AU	WO	05/013889	A2	02-17-2005			<input type="checkbox"/>
	AV	WO	04/009625	A2	01-29-2004			<input type="checkbox"/>
	AW	WO	01/053457	A2	07-26-2001			<input type="checkbox"/>
	AX	WO	99/40191	A1	08-12-1999			abst. only <input type="checkbox"/>
	AY	WO	99/27944	A1	06-10-1999			<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

60959587

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/698,099
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1648
				Examiner Name	Michelle S. Homing
Sheet	2	of	3	Attorney Docket Number	015270-008930US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
/MH/	AZ	DE LUSTIG et al., "Peripheral Markers and Diagnostic Criteria in Alzheimer's Disease: Critical Evaluations," <u>Reviews in Neurosciences</u> , 5:213-225 (1994).	<input type="checkbox"/>	
	BA	FARRER, M. J., "Genetics of Parkinson disease: paradigm shifts and future prospects," <u>Nat. Rev. Genet.</u> , 7:306-318 (2006).	<input type="checkbox"/>	
	BB	GOLDSBY et al., "Vaccines," Chapter 18 from <i>Immunology, 4th Edition</i> , W.H. Freeman and Company, New York, pages 449-465 (2000).	<input type="checkbox"/>	
	BC	HANSEN et al., "Neurobiology of Disorders with Lewy Bodies," chapter 14, pages 173-182 from <i>Functional Neurobiology of Aging</i> , Hof et al., eds., Academic press (2001).	<input type="checkbox"/>	
	BD	HSIAO, K. K., "From prion diseases to Alzheimer's disease," <u>J. Neural. Transm. Suppl.</u> , 49:135-144 (1997).	<input type="checkbox"/>	
	BE	IRIZARRY et al., "nigral and Cortical Lewy Bodies and Dystrophic Neurites in Parkinson's Disease and Cortical Lewy Body Disease Contain α -synuclein Immunoreactivity," <u>J. Neuropathology and Exp. Neurology</u> , 57(4):334-337 (1998).	<input type="checkbox"/>	
	BF	KOTZBAUER et al., "Lewy Body Pathology in Alzheimer's Disease," <u>J. Mol. Neuroscience</u> , 17(2):225-232 (2001).	<input type="checkbox"/>	
	BG	KUBY, J., pages 92-97 and 110 from <i>Immunology, Third Edition</i> , W.H. Freeman & Co., New York, (1997).	<input type="checkbox"/>	
	BH	LIPPA et al., "Antibodies to α -synuclein Detect Lewy Bodies in Many Down's Syndrome Brains with Alzheimer's Disease," <u>Ann. Neurology</u> , 45:353-357 (1999).	<input type="checkbox"/>	
	BI	LUCKING et al., "Review: Alpha-synuclein and parkinson's disease," <u>Cell Mol. Life Sci.</u> , 57:1894-1908 (2000).	<input type="checkbox"/>	
	BJ	MA et al., " α -Synuclein aggregation and neurodegenerative diseases," <u>J. Alzheimer's Disease</u> , 5:139-148 (2003).	<input type="checkbox"/>	
	BK	MASLIAH et al., "Effects of α -Synuclein Immunization in a Mouse Model of Parkinson's Disease," <u>Neuron</u> , 46:857-868 (2005).	<input type="checkbox"/>	
Examiner Signature			Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete If Known		
			Application Number	10/698,099	
			Filing Date	October 31, 2003	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1648	
			Examiner Name	Michelle S. Horning	
Sheet	3	of	3	Attorney Docket Number	015270-008930US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/MH/	BL	MUNCH et al., "Potential neurotoxic inflammatory responses to A β vaccination in humans," <u>J. Neural. Transm.</u> , 109:1081-1087 (2002).	<input type="checkbox"/>
	BM	PRIMAVERA et al., "Brain Accumulation of Amyloid- β in Non-Alzheimer Neurodegeneration," <u>J. Alzheimer's Disease</u> , 1:183-193 (1999).	<input type="checkbox"/>
	BN	VICKERS, J. C., "A Vaccine Against Alzheimer's Disease, Developments to Date," <u>Drugs Aging</u> , 19(7):487-494 (2002).	<input type="checkbox"/>
	BO	WAKABAYASHI et al., " α -Synuclein immunoreactivity in flial cytoplasmic inclusions in multiple system atrophy," <u>Neuroscience Letters</u> , 249:180-182 (1998).	<input type="checkbox"/>
	BP	WAKABAYASHI et al., "Widespread occurrence of α -synuclein/NACP-immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies," <u>Neuropathology and Applied Neurobiology</u> , 25:363-368 (1999).	<input type="checkbox"/>
	BQ	WAKABAYASHI et al., "Accumulation of α -synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy," <u>Acta Neuropathol.</u> , 96:445-452 (1998).	<input type="checkbox"/>
	BR	Websters New World Dictionary, definition of "prophylactic", 3rd College edition, page 1078 (1988).	<input type="checkbox"/>

Examiner Signature	/Michelle Horning/	Date Considered	05/24/2007
-----------------------	--------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

